ALS clinician researcher at Massachusetts General Hospital with specific interests in markers of disease in early familial ALS and the gut microbiome in ALS
Joined December 2018
- Tweets150
- Following139
- Followers383
- Likes100
Exciting to provide clinical and research updates to our patients- from Amylyx and Tofersen to Prevent ALS! youtu.be/kaBwt3YoqsU
Katharine Nicholson retweeted
Stole this from an excellent talk by @KNicholsonMD - who can tell me how to have a diet that supplements the things in blue, and suppresses the things in orange?
Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS | Biogen investors.biogen.com/news-re…
Katharine Nicholson retweeted
Join Dr. Richard Bedlack @dukealsclinic and Dr. Merit Cudkowicz @MGHNeurology for Part 6 of the #ALS Drug Development Webinar Series on September 15th conta.cc/3z5Q0v5
Katharine Nicholson retweeted
30 signed Lou Gehrig Day baseballs across MLB + a one-of-a kind experience. All net proceeds will benefit the Expanded Access Protocol Program (EAP) at the Sean M. Healey & AMG Center for ALS.
The #LouGehrigDay Auction is live now: atmlb.com/3yULkb5
Katharine Nicholson retweeted
A big heartfelt thank you to @RepAuchincloss for taking time out of his busy schedule today to meet with me and my family. I truly believe he will do everything in his power to help the ALS community. As I said today WE NEED YOU! Thank you! ❤️
Katharine Nicholson retweeted
I can't emphasize this enough-the ALS Principles are the boundaries that people living with ALS have needed. 'What we allow will continue' and we must make sure we are building clear paths towards treatments for a horrendous disease, always working together so we get there faster
The Morris ALS Principles were developed by those most impacted by ALS as a social contract that will drive a path forward. They show how each of us can do better so that treatments and cures are a reality and not an empty promise. bit.ly/3fzHU4F
Katharine Nicholson retweeted
Join us this Friday at 3:30 PM ET for Part 4 of the #ALS Drug Development Webinar Series: Site Considerations conta.cc/3eRQY4I
Katharine Nicholson retweeted
Join us on May 17th at 2 PM ET for An Update on the CENTAUR Trial: a Trial of AMX0035 in ALS conta.cc/3vSLIoe
Katharine Nicholson retweeted
We’re excited to announce our intention to submit a Marketing Authorization Application (MAA) for AMX0035 for the treatment of #ALS to the European Medicines Agency & the start of a Phase 3 trial in Europe & the U.S. bwnews.pr/2RAkHXS
Katharine Nicholson retweeted
Today, we are excited to share news of our plans to submit a New Drug Submission for AMX0035 for the treatment of #ALS with Health Canada in the first half of 2021. This decision is based on the positive clinical data from the CENTAUR trial, and feedback from Health Canada.
Katharine Nicholson retweeted
Coya Therapeutics announces merger with Nicoya Health and close of a $10 million Series A financing. Proceeds will be used to advance Coya's lead therapeutic program, ALS001: an off-the-shelf, autologous, expanded Treg cell therapy for ALS. #ALS bit.ly/36yMrRl
Katharine Nicholson retweeted
2020 was a turning point for #ALS research- thank you to our supporters and people who inspire our research @iamalsorg @sandymorris333 @alsassociation @MDAorg @MGHNeurology youtu.be/Qhvl1jEEldg
Katharine Nicholson retweeted
If the ALSFRS-R is the gold standard, it is a chocolate coin in gold foil masquerading as such and someday will be devoured by more objective measures
- a patient with a flair for the dramatic
#alsmndsymp @MGHNeurology @KNicholsonMD
So can we stop using this as the “gold standard” for measuring treatment efficacy and progression? #alsmndsymp 4/4
Katharine Nicholson retweeted
In addition, a team from Mass General including @sheenachew, @PaganoniMDPhD, @LidiaMouraNVL and @KNicholsonMD has a poster on patient-reported outcomes and the ALSFRS-R and ABC scales.
Download clinical trial poster abstracts here: tinyurl.com/y3zmocgp
Exciting new data presented by @PaganoniMDPhD from @AmylyxPharma and @ENCALS collaboration to predict a broader ALS population may have an up to 11.5 mo survival benefit from AMX0035! @MGHNeurology #alsmndsymp #HealeyHope
Katharine Nicholson retweeted
Today at the Intl. Symposium on ALS/MND check out the latest findings from @GSVLab together with @tpetrozziello assessing how DRP1 and tau affect mitochondrial fragmentation in ALS.
More info: tinyurl.com/yx9gbz3v
#HealeyHope #ALSSymp
Thank you @PaganoniMDPhD @AmylyxPharma for presenting positive Centaur phase 2 results at #alsmndsymp with BOTH significant survival and functional benefits seen. Very exciting results for a well designed trial! Thank you to patients and caregivers from the study! @MGHNeurology
A consistent robust treatment effect on CSF biomarkers of neuroinflammation/neuronal injury (reduced) and neuroprotection (increased) was seen in the Phase 3 @BrainstormCell trial. Important learnings for the entire ALS field! @MGHNeurology #alsmndsymp #HealeyHope
Katharine Nicholson retweeted
The Symposium on ALS/MND poster session on genetics & genomics features work on early markers of disease in familial ALS from @KNicholsonMD, Dr. James Berry, and collaborators at @WashUNeurology & @MayoClinicNeuro Jacksonville.
#HealeyHope #ALSSymp tinyurl.com/y6nnxyy2